To add to this, why would LL fight this late in the game (with her presentations during the spring at Mt Sinai amongst others) if the data wasn’t impressive? Also, remember the podcast KA did in May!
Plus LL getting inducted in Asian Hall of Fame for her work on brain cancer vaccine last month.
We must remember that UK and EU have accepted new endpoints and approvals in those regions are over 90% certain. That alone gets us to a 2-3 billion market cap minimum. If our (US) clinical trials website gets updated with our new endpoints in Q1, we deserve a market cap of close to 5 billion, IMO.
I believe TLD+publication will to be released in Q1. If it doesn’t then I start to question their intent. Not sure many shareholders will stick around any longer regardless of what they say about Flaskworks and it’s potential.
Either way, if they are not acquired in 2022 I am not sure this management will be able to fulfill the tremendous promise this vaccine offers. Again, I say time is money. With the promise of AI amongst other things, a company like Merck can really take this to another level.